Oct 14 (Reuters) – Vanda Pharmaceuticals Inc: * VANDA PHARMACEUTICALS PROVIDES UPDATE ON VQW-765 CLINICAL DEVELOPMENT PROGRAM * VANDA PHARMACEUTICALS – PHASE III STUDY OF VQW-765 DID NOT MEET PRIMARY
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
Oct 14 (Reuters) - Anthropic told investors its third-quarter revenue jumped to $16.8 billion and…
By Ann Saphir SAN FRANCISCO, Oct 14 (Reuters) - The Federal Reserve will probably need…
Oct 14 (Reuters) - Anthropic said on Wednesday it would add official US voting information…
Here are the top stories and upcoming coverage plans for Reuters text service as of…
Oct 15 (Reuters) - GDS Global Ltd: * GDS GLOBAL LIMITED GDS SECURES S$12.1 MILLION…
Oct 14 (Reuters) - Rocket Lab on Wednesday said the inaugural launch of its new,…